The Risk of Severe Salicylate Poisoning Following the Ingestion of Topical Medicaments Or Aspirin

Total Page:16

File Type:pdf, Size:1020Kb

The Risk of Severe Salicylate Poisoning Following the Ingestion of Topical Medicaments Or Aspirin Postgrad Med J7 1996; 72: 109-112 C) The Fellowship of Postgraduate Medicine, 1996 Postgrad Med J: first published as 10.1136/pgmj.72.844.109 on 1 February 1996. Downloaded from The risk of severe salicylate poisoning following the ingestion of topical medicaments or aspirin Thomas YK Chan Summary The main objective of this retrospective Apart from isolated reports of severe study was to assess the risk of severe salicylate salicylate poisoning after ingesting an poisoning amongst patients who had self- unusually large amount of a medicinal poisoned themselves with topical medicaments oil, there are no published data on the or aspirin tablets. threat arising from attempted suicide with topical medicaments containing Patients and methods methyl salicylate or wintergreen oil com- pared with aspirin tablets. In this retro- The Prince ofWales Hospital is the sole general spective study, the admission plasma teaching hospital in the New Territories East, salicylate concentrations and clinical Hong Kong, serving a population of about 1.2 presentations were compared in 80 sub- million in 1994. Also situated in this region are jects who had taken aspirin tablets two Vietnamese refugee camps. (n = 42) or topical medicaments (n = 38). From January 1991 to December 1993, all The proportions of subjects being symp- patients admitted to our general medical wards tomatic were similar in the two groups. with a history of salicylate ingestion were Although the admission plasma salicylate included in the study. They were identified concentrations were generally higher in from our previous studies of the pattern of subjects who had ingested aspirin tablets, acute poisoning4'6'7 or the registry of requests the two highest readings (4.3 and 3.5 for plasma salicylate measurements. Patients mmol/l) belonged to two of the subjects who had taken unknown analgesics/antipyr- who had taken topical medicaments. etics but with undetectable plasma salicylate Because of its liquid, concentrated form concentrations (< 0.1 mmol/ 1) were excluded. and lipid solubility, methyl salicylate The hospital records of these patients were poses the threat of severe, rapid-onset reviewed. Demographic data and information salicylate poisoning. The toxic potential regarding agents used, clinical features, treat- oftopical medicaments containing meth- ment given and outcome were noted. The http://pmj.bmj.com/ yl salicylate or wintergreen oil should be identification of the agents responsible was fully appreciated by both physicians and based on the history from the patient/ the general public. witnesses, labelling on the containers and/or the clinical features. For patients who had Keywords: salicylate poisoning, poisoning, topical concomitantly taken more than one agent, only medicament, methyl salicylate, aspirin signs and symptoms that could be attributed to salicylates were considered. on September 29, 2021 by guest. Protected copyright. Salicylate poisoning remains a common prob- Results lem in many Western countries with an app- reciable morbidity and mortality." 2 This is due Eighty patients who had ingested various kinds largely to the ready availability of aspirin and of aspirin tablets (n = 42) or topical medica- the frequent occurrence of salicylates in unex- ments containing methyl salicylate or winterg- pected sources such as cold and allergy reen oil (n = 38) were studied. The main preparations, oil of wintergreen, rubefacients reasons for self-poisoning included emotional for rheumatism and ointments for psoriasis.3 upset, social crisis and physical illness. The more serious incidents in adults normally Psychiatric assessment indicated that three of occur following the ingestion of large doses of the patients who had ingested tablet formula- aspirin in its various formulations - solid, tions were suffering from anxiety and/or Department of Clinical soluble, sustained release and liquid prepara- depression. Pharmacology, The tions. As can be seen in table 1, most ofthe Chinese Chinese University of In Hong Kong, aspirin and other analgesics subjects included in this study had taken Hong Kong, Prince of accounted for 10-18% of the adult cases of aspirin tablets, whereas most ofthe Vietnamese Wales Hospital, self-poisoning admitted to the Prince of Wales subjects had taken topical medicaments. Sub- Shatin, New Hospital during 1988 to 1991.4 Topical jects who had taken aspirin tablets tended to Territories, Hong Kong medicaments containing wintergreen oil or present with mixed overdosage involving other TYK Chan methyl salicylate were involved in about half of drugs or chemicals. Six ofthe subjects from the the patients who were suspected to have topical medicament group went missing within Accepted 5 September 1995 ingested salicylates.5 48 hours of admission. The two groups were 110 Chan otherwise comparable with regard to age, time The plasma salicylate concentration in rela- lapsed between ingestion and admission to an tion to the time of ingestion is shown in the emergency department, the use of gastric figure. Twenty-four subjects were excluded Postgrad Med J: first published as 10.1136/pgmj.72.844.109 on 1 February 1996. Downloaded from lavage or ipecac, the proportion having symp- because the test was not requested (n = 1), the toms of salicylate poisoning and duration of time of ingestion was not known (n = 6) or hospital stay. The alleged amounts ofaspirin or plasma salicylate concentrations were below salicylates ingested by the two groups of subj- 0.1 mmol/1 (n = 17). In the 11 patients who ects are summarised in table 2. had two or more measurements (six had taken aspirin tablets), the highest plasma level was used for analysis. Subjects who had taken aspirin tablets tended to have higher plasma salicylate concentrations than subjects who had Table 1 Clinical details of 80 subjects who self-poisoned themselves taken topical medicaments, although the two with two different formulations of salicylates subjects with the highest levels belonged to the Tablets Topical medicament latter group. (n = 42) (n = 38) Urinary alkalinisation8 was considered neces- sary in the two patients with moderate to severe Men:women ratio 8:34 7:31 of after Chinese subjects 39 (93%) 4 (10%) symptoms salicylate poisoning inges- Vietnamese subjects 2 (5%) 34(90%) ting 30 'Anacin' tablets (plasma salicylate con- Age (years) 22 (15-80)* 22 (15-86)* Ingestion-admission intervals (h) 3 (0.5-48)* 3 (0.5- 16)* Mixed overdosage 27 (64%)** 10 (26%)t 5.0 Gastric lavage/ipecac 32(76%) 29(76%) Plasma salicylate levels (mmol/ 1) o 4.5 not requested 1 (2%) 0 E <0.1 4(10%) 13(34%) E 4.0 0.1-1.0 13 (31%) 18(48%) c 1.1-2.1 16(38%) 5 (13%) .° 3.5 1- ~~0 > 2.2 8 (19%) 2(5%) 3-0 Severity ofsalicylate poisoningtf c4 o no symptoms 17(40%) 13(34%) 0 0 mild 24 (58%) 24 (64%) 20O -8 °00 80 o moderate to severe 1 (2%) 1 (2%) Duration ofstay (days) 2 (1 -4)* 2 (1 -5)* 0 Outcome (%) C 1-5 found missing 0 6 (16%) _co discharge against medical advice 3(7%) 1(3%) 02.00 transferred to other units 2(5%) 1(3%) E<, 0-5 -o home 37 (88%) 30(79%) L 0 *Medians and ranges. **Other agents included paracetamol or paracetamol- 85 lo 15 2 30 35 40 45 50 containing drugs (n = 13), hypnotics (n = 7), alcohol (n = 7), Chinese proprietary Hours after ingestion medicines (n = 4), tricyclic antidepressants (n = 2), antacids (n = 2), and household products (n = 2). tOther agents included alcohol (n = 4), antibiotics (n = 3), Figure Plasma salicylate concentration in relation to paracetamol (n = 2), and household products (n = 2). ttSymptoms including nausea, the time ofingestion in 56 subjects who had taken http://pmj.bmj.com/ vomiting, tinnitus, deafness, sweating, hyperventilation and respiratory aspirin tablets (0, n = 36) or topical medicaments (0, alkalosis/metabolic acidosis. n = 20). Table 2 The alleged amounts of aspirin tablets or topical medicaments ingested by 80 subjects Dosageform Quantity on September 29, 2021 by guest. Protected copyright. Tabletformulations (n = 42) Cortal (n = 21) 10tab = 8; 11-20 = 11; > 21 = 1;NK = 1 Anacin (n = 8) 10 tab = 3*; 11 -20 = 2; > 21 = 2; NK = 1 Aspirin**(n =4) 10 tab = 1; > 21 = 1; NK = 2 Coricidin(n= 1) 11-20tab= 1 Excedrin (n= 1) 11 -20 tab = 1 Unspecified (n = 7) 11 -20 tab = 1; > 21 =2; NK= 4 Topical medicaments (n = 38) White Flower Medicine Oil (n = 22)t < 10 ml = 5; 11 -20 = 2; > 21 = 2; NK = 13 Red Flower Oil (n = 5) 11 -20 ml = 1; NK = 4 Axe Brand Universal Oil (n = 1) 11-20 ml = 1 Black Man Oil (n = 1) NK= 1 Unspecified medicated oils (n = 9) < 10 ml = 1; 11 -20 = 2; > 21 = 2; NK = 4 NK = not known. *One subject also took two aspirin tablets. **The strength of the tablet was not specified. tOne subject also took an unknown amount ofan unspecified medicated oil. Cortal (acetylsalicylic acid 500 mg, caffeine 30 mg), Anacin (aspirin 400 mg, caffeine 32 mg), Coricidin (chlorpheniramine 2mg, acetylsalicylic acid 388.8 mg, caffeine 32.4 mg), Excedrin (acetaminophen 250 mg, aspirin 250 mg, caffeine 65 mg). White Flower Medicine Oil (wintergreen oil 40%, menthol crystal 30%, eucalyptus oil 18%, camphor 6%, lavender oil 6%), Red Flower Oil (wintergreen oil 67%, turpentine oil 22%, cinnamic aldehyde 5%, cinnamon leaf oil 4%, citronella oil 2%), Axe Brand Universal Oil (methyl salicylate 15%, menthol crystals 20%, eucalyptus oil 15%, essential oil 12%, camphor 5%), Black Man Oil (wintergreen oil 28%, turpentine oil 70%, thymol crystal 1 %, citronella oil 1 %). Salicylate poisoning 111 centration 1.9 mmol/l seven hours post- fatal,"4 although the lethal dose in adults is ingestion) or an unknown amount of 'Red estimated at 30 m1.'4"15 Ingestion of 100 ml of Flower Oil' (4.3 mmol/1 at 11.5 hours).
Recommended publications
  • Methyl Salicylate and Menthol | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Methyl Salicylate and Menthol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US AMPlify Relief MM [OTC]; BenGay [OTC]; Calypxo HP [OTC]; Capasil [OTC]; Icy Hot [OTC]; Kwan Loong Pain Relieving [OTC]; Precise [OTC]; Salonpas Arthritis Pain [OTC]; Salonpas Jet Spray [OTC]; Salonpas Massage Foam [OTC]; Salonpas Pain Relief Patch [OTC]; Thera-Gesic Plus [OTC]; Thera-Gesic [OTC] What is this drug used for? It is used to ease muscle and joint aches and pain. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If your skin is damaged or has open wounds. Do not put on damaged skin or open wounds. If you are taking any other NSAID. If you are taking a salicylate drug like aspirin. If you are pregnant, plan to become pregnant, or get pregnant while taking this drug. This drug may cause harm to an unborn baby if taken at 20 weeks or later Methyl Salicylate and Menthol 1/7 in pregnancy. If you are between 20 to 30 weeks of pregnancy, only take this drug if your doctor has told you to. Do not take this drug if you are more than 30 weeks pregnant.
    [Show full text]
  • Issue 3 Combinations Were Banned in the Month of March, 2016
    344 FDC’s REGIMEN Banned in CHIPS India The Health Ministry has banned 344 ‘Fixed HIP C S ✪ Dose Combination’ (FDC) ✪ drugs, leading to an immediate suspension of the manufacturing and sale of some popular medicines in India. Fixed drug combinations have mushroomed in the market as the Pharmaceutical companies ✪ in their quest for newer products and to increase G ✪ UNTUR FR Drug Information News Letter its sales, mix and match ingredients into a single OM C EATION molecule to market them as newer remedies. 344 of such ONCEPT TO CR Jan-Mar 2016, Volume 1, Issue 3 combinations were banned in the month of March, 2016. Keeping in view of the Risk that is associated with these Fixed drug combinations and safer alternatives being available in the market, the Ministry moved ahead with its decision to ban all the 344 fixed drug combinations. Simethicone, *fixed dose combination of Magaldrate + Papain + Fungul Here is the list of 344 banned fixed Drug Combinations in India Diastase + Simethicone, *fixed dose combination of Rabeprazole + Zinc + Domperidone, *fixed dose combination of Famotidine + Oxytacaine + *Aceclofenac + Paracetamol + Rabeprazole, *Nimesulide + Diclofenac, *Diphenoxylate + Atropine + Furazolidone, * Combikit of Fluconazole Magaldrate,*fixed dose combination of Ranitidine + Domperidone + *Nimesulide + Cetirizine + Caffeine, *Nimesulide + Tizanidine, Tablet, Azithromycin Tablet and Ornidazole Tablets, *Ciprofloxacin + Simethicone,*fixed dose combination of Alginic Acid + Sodium *Paracetamol + Cetirizine + Caffeine*Diclofenac +
    [Show full text]
  • Ascorbic Acid/ Paracetamol/ Phenylephrine Hydrochloride PSUSA/00000255/202006 List of Nationally Authorised Medicinal Products
    11 February 2011 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance: ascorbic acid/paracetamol/phenylephrine hydrochloride Procedure no.: PSUSA/00000255/202006 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Member State where Product full name MRP/DCP or CP National Authorisation MAH of product in the member product is (in authorisation country) Authorisation number Number state authorised OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/06 KFT. HU OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/05 KFT. HU OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/11 KFT. HU Blackcurrant Coldrex Powders not available PL 02855/0271 OMEGA PHARMA LTD UK AZIENDE CHIMICHE RIUNITE TACHIFLUDEC polvere per soluzione orale gusto ANGELINI FRANCESCO - menta not available 034358073 A.C.R.A.F. S.P.A. IT AZIENDE CHIMICHE RIUNITE TACHIFLUDEC polvere per soluzione orale gusto ANGELINI FRANCESCO - menta. not available 034358085 A.C.R.A.F. S.P.A. IT List of nationally authorised medicinal products Page 2/8 COLDREX MAXGRIP MENTHOL & BERRIES, 1000 mg/70 mg/10 mg, suukaudse lahuse pulber kotikeses not available 798812 RICHARD BITTNER AG, EE GLAXOSMITHKLINE CONSUMER HEALTHCARE Beechams Cold & Flu Hot Lemon not available MA 932/00103 (UK) TRADING LIMITED MT OMEGA PHARMA HUNGARY Coldrex citrom ízű por belsőleges oldathoz not available OGYI-T-1715/01 KFT.
    [Show full text]
  • Management of Poisoning
    MOH CLINICAL PRACTICE GUIDELINES December/2011 Management of Poisoning Health Ministry of Sciences Chapter of Emergency College of College of Family Manpower Authority Physicians Physicians, Physicians Academy of Medicine, Singapore Singapore Singapore Singapore Medical Pharmaceutical Society Society for Emergency Toxicology Singapore Paediatric Association of Singapore Medicine in Singapore Society (Singapore) Society Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Principles of management of acute poisoning – resuscitating the poisoned patient GPP In a critically poisoned patient, measures beyond standard resuscitative protocol like those listed above need to be implemented and a specialist experienced in poisoning management should be consulted (pg 55). GPP D Prolonged resuscitation should be attempted in drug-induced cardiac arrest (pg 55). Grade D, Level 3 1 C Titrated doses of naloxone, together with bag-valve-mask ventilation, should be administered for suspected opioid-induced coma, prior to intubation for respiratory insuffi ciency (pg 56). Grade C, Level 2+ D In bradycardia due to calcium channel or beta-blocker toxicity that is refractory to conventional vasopressor therapy, intravenous calcium, glucagon or insulin should be used (pg 57). Grade D, Level 3 B Patients with actual or potential life threatening cardiac arrhythmia, hyperkalaemia or rapidly progressive toxicity from digoxin poisoning should be treated with digoxin-specifi c antibodies (pg 57). Grade B, Level 2++ B Titrated doses of benzodiazepine should be given in hyperadrenergic- induced tachycardia states resulting from poisoning (pg 57). Grade B, Level 1+ D Non-selective beta-blockers, like propranolol, should be avoided in stimulant toxicity as unopposed alpha agonism may worsen accompanying hypertension (pg 57).
    [Show full text]
  • Poison Prevention Packaging: a Guide for Healthcare Professionals
    PPooiissoonn PPrreevveennttiioonn PPaacckkaaggiinngg:: AA GGuuiiddee FFoorr HHeeaalltthhccaarree PPrrooffeessssiioonnaallss REVISED 2005 CPSC 384 US. CONSUMER PRODUCT SAFETY COMMISSION, WASHINGTON, D.C. 20207 THIS BROCHURE BROUGHT TO YOU BY: U.S. CONSUMER PRODUCT SAFETY COMMISSION Washington, DC 20207 Web site: www.cpsc.gov Toll-free hotline: 1-800-638-2772 The U.S. Consumer Product Safety Commission (CPSC) is a federal agency that helps keep families and children safe in and around their homes. For more information, call the CPSC’s toll-free hotline at 1-800-638-2772 or visit its website at http://www.cpsc.gov. Poison Prevention Packaging: A Guide For Healthcare Professionals (revised 2005) Preface The U.S. Consumer Product Safety Commission (CPSC) administers the Poison Prevention Packaging Act of 1970 (PPPA), 15 U.S.C. §§ 1471-1476. The PPPA requires special (child-resistant and adult-friendly) packaging of a wide range of hazardous household products including most oral prescription drugs. Healthcare professionals are more directly involved with the regulations dealing with drug products than household chemical products. Over the years that the regulations have been in effect, there have been remarkable declines in reported deaths from ingestions by children of toxic household substances including medications. Despite this reduction in deaths, many children are poisoned or have "near-misses" with medicines and household chemicals each year. Annually, there are about 30 deaths of children under 5 years of age who are unintentionally poisoned. Data from the National Electronic Injury Surveillance System (a CPSC database of emergency room visits) indicate that in 2003, an estimated 78,000 children under 5 years of age were treated for poisonings in hospital emergency rooms in the United States.
    [Show full text]
  • 1. Generic Name Paracetamol, Phenylephrine, Chlorpheniramine Maleate, Sodium Citrate, Menthol 2. Qualitative and Quantitative Co
    1. Generic Name Paracetamol, Phenylephrine, Chlorpheniramine maleate, Sodium citrate, Menthol 2. Qualitative and Quantitative composition Paracetamol 125 mg Phenylephrine 5 mg Chlorpheniramine maleate 1 mg Sodium citrate 60 mg Mentholated flavoured syrupy base q.s. 3. Dosage form and strength Oral syrup containing Paracetamol 125 mg, Phenylephrine 5 mg, Chlorpheniramine maleate 1 mg. 4. Clinical particulars 4.1 Therapeutic indication Sinarest Syrup is indicated in children below 40 kg weight for: • Relief of nasal and sinus congestion. • Relief of allergic symptoms of the nose or throat due to upper respiratory tract allergies. • Relief of sinus pain and headache. • Adjunct with antibacterial in sinusitis, tonsillitis and otitis media. 4.2 Posology and method of administration Children of age between 2 to 12 years (body weight- 6 - 40 kg): The usual recommended dose is as shown in the table below which will be given to the patient: Weight Age Dose 6 – 22.9 2 – 7 years 5 ml BID 11.9 – 40 7 – 12 years 5 ml TID 4.3 Contraindication The use of Sinarest syrup is contraindicated in patients with: Hypersensitivity to any of the ingredients of the formulation. Severe hypertension. 4.4 Special warnings and precautions for use In case a hypersensitivity reaction occurs which is rare, Sinarest syrup should be discontinued. Sinarest syrup contains Paracetamol and therefore should not be used in conjunction with other Paracetamol containing products. Sinarest syrup should be used with caution in patients with renal or hepatic dysfunction, diabetes mellitus, hyperthyroidism, cardiovascular problems, epilepsy and closed angle glaucoma. 4.5 Drug interactions Clinically significant drug interactions may occur on concomitant administration of Sinarest syrup with monoamine oxidase inhibitors, tricyclic antidepressants, beta-adrenergic agents, and methyldopa, reserpine and veratrum alkaloids.
    [Show full text]
  • Topical Analgesics: Expensive and Avoidable
    TOPICAL ANALGESICS: EXPENSIVE AND AVOIDABLE FAST FOCUS Some very expensive topical creams and gels are creeping into the workers’ compensation Close management of custom compounds prescription files. Previously, the issue of custom compounds was highlighted and the has decreased their prevalence in workers’ attention to these prescriptions has resulted in a decrease in the number of prescriptions compensation. But private-label topicals and homeopathic products have filled the void. seen. However, the price of these compounds has increased significantly. Neither is FDA-approved. Both warrant close monitoring because of their high costs and In addition to the compounds that are still being prescribed, other topical products are lack of proven efficacy. increasingly seen in the workers’ compensation setting. In this article, a spotlight is turned on to expose more expensive topicals — private-label analgesics and homeopathic products. 24 | RxInformer FALL 2013 SUMMARY OF PRIMARY ISSUES Issue Custom Compounds Private-Label Analgesics Homeopathic Products NDCs Available FDA-approved Proven clinical benefit Prepared by compounding — — pharmacy for a specific patient Contain high levels of NSAIDs — — Contain 2-3x the FDA-approved concentration of methyl salicylate — and/or menthol Can cause skin burns — Prescribers unaware of compound ingredients Prescribers unaware of high costs Expiration dating required — — TOPICAL PRIVATE-LABEL PRODUCTS FINANCIAL CONCERNS There are private-label companies marketing products similar to inexpensive, over- When compared with comparable over-the- the-counter products, but with catchy names, inflated claims and prices. Private-label counter (OTC) preparations, the private-label topical compounds are products containing OTC ingredients such as high-potency products’ prices are stunning.
    [Show full text]
  • Experiment 22 Synthesis of Aspirin and Oil of Wintergreen
    Experiment 22 Synthesis of Aspirin and Oil of Wintergreen GOALS: In this two-week experiment the important area of organic chemistry will be illustrated by the preparation and characterization of two compounds. The usefulness of functional groups will be illustrated as well as the use of NMR, IR, and melting point in characterizing a product. The analysis will be done next week in Experiment 23. INTRODUCTION: Synthesis and use of organic compounds is an extremely important area of modern chemistry. Approximately half of all chemists work with organic chemicals. In everyday life, many if not most of the chemicals you come in contact with are organic chemicals. Examples include drugs, synthetic fabrics, paints, plastics, etc. Synthesis of Aspirin and Methyl Salicylate. The two compounds we will be preparing, aspirin (acetylsalicylic acid) and oil of wintergreen (methyl salicylate), are both organic esters. An ester is a compound that is formed when an acid (containing the –COOH group) reacts with an alcohol (a compound containing an –OH group). O O + C O C + O Eqn 1 R O H 1 H R2 R O R H H 1 2 ester water acid alcohol Here R1 and R2 represent groups such as CH3– or CH3CH2–. The reaction type shown above may be called a condensation reaction because the small molecule H2O is eliminated from the reactants while the remaining bits of the reactants condense together to give the main product. This reaction may also be called an esterification, since the product of the reaction is an ester, a compound containing the CO2R group (see chapter 20 for definitions of acids, esters, and alcohols).
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Risk Perception of Medicinal Marijuana in Medical Students from Northeast Mexico[Version 1; Referees: Awaiting Peer Review]
    F1000Research 2017, 6:1802 Last updated: 04 OCT 2017 RESEARCH ARTICLE Risk perception of medicinal marijuana in medical students from northeast Mexico [version 1; referees: awaiting peer review] Sandra Castillo-Guzmán1, Dionicio Palacios-Ríos1, Teresa A. Nava-Obregón1, Julio C. Arredondo-Mendoza1, Olga V. Alcalá-Alvarado1, Sofía A. Alonso-Bracho1, Daniela A. Becerril-Gaitán1, Omar González-Santiago 2 1Pain and Palliative Care Clinic, Anesthesiology Service, Hospital Universitario Dr. José E. González y Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico 2Postgraduate in Pharmacy, Faculty of Chemical Science, Universidad Autónoma de Nuevo León, San Nicolas de Los Garza, Nuevo León, Mexico v1 First published: 04 Oct 2017, 6:1802 (doi: 10.12688/f1000research.12638.1) Open Peer Review Latest published: 04 Oct 2017, 6:1802 (doi: 10.12688/f1000research.12638.1) Referee Status: AWAITING PEER Abstract Background. Several studies have shown support from the public toward the REVIEW use of medicinal marijuana. In this cross-sectional study, we assess the risk perception to medicinal marijuana in a sample of medical students. Discuss this article Methods. To estimate risk perception, a visual scale that ranges from 0 cm Comments (0) (without risk) to 10 cm (totally risky) was used. Risk perception was expressed as the median of the cm marked over the scale. Differences among groups was tested with the Mann-Whitney and Kruskal-Wallis tests, as appropriate. Results. 283 students participated in the study. Risk perception to medicinal marijuana was 4.22, paracetamol 1.56 and sedatives 5.0. A significant difference in risk perception was observed in those that self-reported to smoke and consume alcohol.
    [Show full text]
  • Perception of the Risk of Medicinal Marijuana in Postgraduate Medical Residents[Version 1; Peer Review: Awaiting Peer Review]
    F1000Research 2019, 8:381 Last updated: 14 MAY 2021 RESEARCH NOTE Perception of the risk of medicinal marijuana in postgraduate medical residents [version 1; peer review: awaiting peer review] Sandra Castillo-Guzmán , Dionicio Palacios Ríos, Teresa Adriana Nava Obregón, Daniela Alejandra Becerril Gaitàn, Keren Daniela Juangorena García, Danya Carolina Domínguez Romero, Misael Jerónimo Reyes Rodríguez Pain and Palliative Care Clinic, Anesthesiology Service, Hospital Universitario Dr.Jose Eleuterio González y Facultad de Medicina de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, 66463, Mexico v1 First published: 04 Apr 2019, 8:381 Open Peer Review https://doi.org/10.12688/f1000research.17394.1 Latest published: 04 Apr 2019, 8:381 https://doi.org/10.12688/f1000research.17394.1 Reviewer Status AWAITING PEER REVIEW Any reports and responses or comments on the Abstract article can be found at the end of the article. Background: Drugs can often cause adverse reactions, and the perception of the risk of prescription drugs could influence prescription behaviour. Methods: This was a prospective cross-sectional study of the perception of postgraduate physicians in training of the risk of using medical marijuana, comparing it with their perception of paracetamol and sedatives. A visual analogue scale with ranges from 0 (no risk) to 10 (totally risky) was used. Results: A total of 197 postgraduate students were evaluated; 48 women and 149 men took part, with a mean age 27.8 years. Among the different specialties, there was a difference with regard to the perception of medical marijuana and paracetamol and all perceived a greater risk with sedatives. There was no evidence of a risk perception of marijuana in relation to factors such as alcohol consumption and smoking.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    PROTOCOL: Cannabidiol for Fibromyalgia AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital DATE: 2020-12-14 Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov Identifier: CLINICAL TRIAL PROTOCOL Cannabidiol for Fibromyalgia The CANNFIB trial Protocol for a randomized, double-blind, placebo-controlled, parallel-group, single-center trial Sponsor Investigator Marianne Uggen Rasmussen (MUR) RN, MPH, PhD; Post-doctoral fellow Primary Investigator and Supervisor Kirstine Amris (KA) MD, DMSc; Senior Rheumatologist CO-investigator and statistical advisor Robin Christensen (RC) MSc, PhD; Professor of Biostatistics and Clinical Epidemiology CO-investigator and advisor Eva Ejlersen Wæhrens (EEW) OT, DMSc; Senior Researcher CO-investigator and advisor Henning Bliddal (HB) MD, DMSc; Professor of Rheumatology Sponsor contact details Marianne Uggen Rasmussen The Parker Institute, Bispebjerg and Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg Phone: +45 38164197 Email: [email protected] 0 PROTOCOL: Cannabidiol for Fibromyalgia AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital DATE: 2020-12-14 Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov Identifier: LIST OF ABBREVIATIONS ACR American college of rheumatology ADL-Q Activities of daily living questionnaire AE Adverse events AMPS Assessment
    [Show full text]